/

Società

An

Non verificato

Anaveon

Di cosa scriviamo

Farmaceutica

5 comunicati stampa

Guarda tutti i comunicati

28/05/2026

Farmaceutica

Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Fonte

Emittente

1.00

0

19/05/2026

Farmaceutica

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

Fonte

Emittente

1.00

0

13/05/2026

Farmaceutica

Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors

Fonte

Emittente

1.00

0

11/05/2026

Farmaceutica

Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Fonte

Emittente

1.00

0

23/03/2026

Farmaceutica

Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0